|Bid||47.67 x 600|
|Ask||47.68 x 1600|
|Day's Range||47.56 - 47.84|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||11.51|
|Dividend & Yield||1.64 (3.41%)|
|1y Target Est||N/A|
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
The European Medicines Agency on Friday recommended approval of Regeneron Pharmaceuticals and Sanofi's new drug Dupixent for atopic dermatitis, a product many analysts see as the most important growth driver for the two companies. Recommendations from the agency's expert committee on new drugs are normally endorsed by the European Commission within a couple of months. Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, often unbearable, itching.